Charles Schwab Investment Management Inc. Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Charles Schwab Investment Management Inc. boosted its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 35.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 253,551 shares of the company’s stock after purchasing an additional 66,386 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Takeda Pharmaceutical were worth $3,357,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Takeda Pharmaceutical during the third quarter worth approximately $601,000. QRG Capital Management Inc. grew its holdings in Takeda Pharmaceutical by 16.8% during the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company’s stock worth $4,364,000 after acquiring an additional 47,490 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter worth about $1,533,000. HighTower Advisors LLC raised its stake in shares of Takeda Pharmaceutical by 199.5% in the 3rd quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock valued at $1,744,000 after purchasing an additional 81,653 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Takeda Pharmaceutical during the third quarter worth about $957,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 0.8 %

NYSE:TAK opened at $15.15 on Friday. The stock has a 50-day simple moving average of $14.12 and a 200 day simple moving average of $13.93. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.31. The company has a market capitalization of $48.19 billion, a price-to-earnings ratio of 37.86, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.